February 13th 2025
Patients with progressive pulmonary fibrosis who received nerandomilast showed improved forced vital capacity from baseline at 52 weeks in the phase 3 FIBRONEER-ILD trial.
Study Examines Success Factors in Finishing Cough Suppression Therapy
2020's Tragedies Propel Student to Examine Race-Based Medical Bias
Contributor: It’s Time to Talk About Paying Clinical Trial Participants More